Gathering the record
Relay is organizing the evidence and source boundaries.
Synthetic 28-amino-acid thymic immunomodulatory peptide
Thymosin Alpha-1 is an immune-modulating peptide studied in serious infections, chronic viral hepatitis, and as an add-on to cancer treatment. It has real human-trial history, but results are mixed: the largest modern Phase 3 trial found no sepsis-mortality benefit, and broad immune-boosting or wellness claims have not been demonstrated.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
Thymosin alpha-1, also called thymalfasin, is a 28-amino-acid peptide studied as an immune-modulating treatment. It has been tested in serious infections, chronic viral hepatitis, and cancer-care combinations.
Researchers want to know whether it can shape immune responses in defined illnesses without simply pushing immunity in one direction. That is more precise than the broad idea of an immune booster.
Human evidence is substantial enough to test the hypothesis but remains mixed. The largest modern trial, involving more than 1,000 people with sepsis, found no reduction in 28-day mortality. Older hepatitis and smaller COVID-19 or oncology studies produced uncertain or setting-specific signals.
A reproducible benefiting subgroup, long-term safety, value alongside modern treatments, and any general wellness effect remain unresolved. Thymosin alpha-1 is not FDA approved, and one disease-specific study cannot justify use in another population.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
A large multicenter trial investigated thymosin alpha-1 as an added treatment in adults with sepsis, comparing it with placebo under blinded conditions.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Controlled Phase 2 and Phase 3 studies span sepsis, hepatitis B, COVID-19, and oncology, alongside human pharmacokinetic research.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Large and disease-specific trials have produced neutral, borderline, or subgroup-dependent findings rather than a consistent general immune benefit.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: The primary mortality result was neutral, and subgroup signals require independent confirmation. The sepsis setting does not establish effects for viral illness, cancer, routine immune support, or wellness use. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
The 1,106-participant, double-blind, placebo-controlled Phase 3 TESTS sepsis trial—which found no reduction in 28-day mortality.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Whether any biomarker-defined subgroup has reproducible benefit, the safety and value of long-term or repeated use, and whether broad wellness claims translate into meaningful clinical outcomes.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
TA1 is better described as an immune modulator than as a simple immune 'booster.'
In the 1,106-person Phase 3 TESTS trial, mortality was nearly the same with TA1 and placebo.
A 97-person Phase 3 trial showed a numerical difference that was not statistically significant.
The signal is worth recording but is not evidence for routine prevention or self-treatment.
A melanoma study had numerical but not conventionally significant signals; a large colorectal trial has no results yet.
Dendritic-cell research links TA1 to TLR9, type-I-interferon, and IDO pathways.
Human trials studied defined illnesses and combination treatments, not healthy-user wellness outcomes.
International use, an NCI dictionary entry, or a clinical-trial listing does not equal FDA approval.
FDA cites possible immunogenicity, peptide-related impurities, API-characterization complexity, and inadequate safety information.
Examples include every-12-hour dosing in sepsis, twice-weekly dosing in hepatitis B, and body-surface-area dosing in a PK study.
A nine-person crossover study found formulation-dependent exposure differences.
Research products and routes do not validate seller-supplied powders or mixed solutions.
Mechanisms
Thymosin alpha-1, also called thymalfasin, is a synthetic analogue of a 28-amino-acid thymic peptide. Laboratory studies link it to dendritic-cell maturation, antigen presentation, T-cell differentiation, Toll-like-receptor signaling, type-I-interferon signaling, and IDO-mediated immune regulation. Clinical evidence is condition-specific and mixed. The 1,106-participant Phase 3 TESTS trial found no reduction in 28-day sepsis mortality or secondary outcomes. Older hepatitis-B trials produced mixed or statistically inconclusive results, a small early-pandemic COVID-19 trial reported a severe-subgroup signal, and oncology studies mainly evaluate TA1 as an adjunct. No FDA-approved TA1 drug or consumer handling standard was identified.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Multicenter, double-blind, randomized, placebo-controlled trial at 22 centers
Adults aged 18–85 years with sepsis according to Sepsis-3 criteria
Among 1,089 participants in the modified intention-to-treat analysis, 28-day mortality was 23.4% with TA1 and 24.1% with placebo. No secondary or safety outcome differed significantly.
Study administration: Protocol-defined 1.6 mg subcutaneous thymosin alpha-1 or placebo every 12 hours for seven days, unless stopped earlier
Limitations: Conducted in China from 2016–2020. Prespecified subgroup signals require independent confirmation and do not replace the neutral primary result.
Double-blind, multicenter, randomized, placebo-controlled add-on trial
One hundred five hospitalized patients with moderate or severe COVID-19
The study reported lower mortality in the severe subgroup with TA1 than placebo. Sixty-seven adverse events occurred in 42 participants, including eight serious events that were deaths.
Study administration: Protocol-defined TA1 or placebo added to the local standard of care used during the early pandemic
Limitations: Small early-pandemic trial; the highlighted result was subgroup-based and background care has changed.
Randomized five-arm adjunct study using dacarbazine, interferon, and two TA1 schedules
Adults with metastatic melanoma
TA1-containing groups showed numerically longer survival and progression-free survival, but reported comparisons did not reach conventional statistical significance. TA1 did not add measurable toxicity.
Study administration: TA1 in protocol-defined combinations with dacarbazine, with or without interferon, versus dacarbazine plus interferon
Limitations: Complex multi-arm study from an older melanoma-treatment era; combination therapy and borderline P values prevent a simple efficacy claim.
Multicenter, randomized, double-blind, placebo-controlled parallel trial
Ninety-seven adults with HBeAg-positive, HBV-DNA-positive chronic hepatitis B
Complete response occurred in 14% of TA1 participants and 4% of placebo participants, but the comparison did not reach conventional statistical significance (P=0.084).
Study administration: Protocol-defined 1.6 mg subcutaneous TA1 or placebo twice weekly for six months
Limitations: This older trial predates modern hepatitis-B treatment standards, was modest in size, and did not confirm earlier efficacy reports.
Randomized three-way crossover comparison of three formulations
Nine healthy adult volunteers
TA1 reached peak serum concentration in roughly one to two hours, had a reported half-life under three hours, and did not meaningfully accumulate over five days. Exposure differed among formulations.
Study administration: Protocol-defined 900 micrograms per square meter subcutaneous TA1 using three research formulations
Limitations: Nine healthy volunteers cannot establish benefit, broad safety, a treatment regimen, or equivalence to compounded products.
Human and murine dendritic-cell experiments with animal transfer models
Cultured immune cells and mouse models; not a clinical population
TA1 influenced dendritic-cell signaling through TLR9 and type-I-interferon pathways and produced both inflammatory-resistance and regulatory-tolerance signals.
Study administration: TA1 exposure in dendritic-cell and animal models
Limitations: Biological plausibility is not a proven human indication and does not support a universal immune-boosting claim.
Sponsor-submitted randomized adjuvant trial after radical colorectal-cancer resection
Planned adults with high-risk stage II or stage III colorectal cancer after surgery
No results were posted by the July 25, 2026 evidence cutoff.
Study administration: Planned TA1 twice weekly for six months plus standard oncology care versus standard care alone
Limitations: A registry entry shows active research, not efficacy, completion, peer review, or regulatory endorsement.
Safety snapshot
FDA identifies significant unresolved safety concerns for compounded TA1.
Other human evidenceThe FDA entry describes unresolved risk and information gaps, not an event-frequency estimate.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
FDA identifies significant unresolved safety concerns for compounded TA1.
Other human evidenceThe FDA entry describes unresolved risk and information gaps, not an event-frequency estimate.
Open sourceThe current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
2026-07-31
2025-01-15 · PMID 39814420 · NCT02867267 · DOI 10.1136/bmj-2024-082583
2022-08-01 · PMID 36042753 · DOI 10.5005/jp-journals-10071-24298
2021-10-22 · NCT05086614
2010-05-01 · PMID 20194853 · DOI 10.1093/annonc/mdp520
2006-10-01 · PMID 16741252 · DOI 10.1182/blood-2006-02-004762
1999-12-01 · PMID 10607256
1999-01-01 · PMID 10027483